頁籤選單縮合
題名 | 心房顫動中風預防新藥--Apixaban=New Oral Anticoagulant for Stroke Prevention in Patients with Atrial Fibrillation--Apixaban |
---|---|
作者 | 劉世清; 李威; 黎天華; 林基福; | 書刊名 | 藥學雜誌 |
卷期 | 29:4=117 2013.12[民102.12] |
頁次 | 頁32-38 |
分類號 | 418.2321 |
關鍵詞 | 心房顫動; 中風; 口服抗凝血藥; Atrial fibrillation; Stroke; Oral anticoagulants; |
語文 | 中文(Chinese) |
中文摘要 | 心房顫動會增加患者中風風險達五倍以上。在臨床指引建議中,口服維生素 K拮抗劑 warfarin可有效用於中高度中風風險心房顫動患者之中風預防。由於 warfarin使用上有諸多限制,多種新機轉的口服抗凝血劑已被研發用於心房顫動患者之中風預防。 Apixaban於2012年12月28日經美國食品藥物管理局核准用於非瓣膜性心房顫動患者之中風或血栓預防。臨床研究結果顯示,與 warfarin相比, apixaban有較佳的預防中風效果及較少的出血事件發生機率。 本篇文章目的在於瞭解新的口服抗凝血劑 apixaban之機轉、療效及安全性,並比較新一代的口服抗凝血劑之特性。 |
英文摘要 | Atrial fibrillation (AF) is associated with a five-fold increase in stroke risk. According to the clinical practice guideline-recommended pharmacotherapy for stroke prevention, warfarin, an oral vitamin K-antagonist anticoagulant, is effective to prevent stroke in AF patients at moderate to high risk of stroke. Nowadays, several new oral anticoagulants have been developed to improve the limitations of warfarin. Apixaban, a new oral anticoagulant, has been approved by U. S. FDA on Dec. 28, 2012 for reducing the risk of stroke, blood clots in patients with non-valvular AF. The results of the clinical study revealed apixaban is superior to warfarin in preventing strokes and causing less bleeding. This article aimed to understand the mechanism, efficacy and safety of apixaban and to compare the general characteristics of these new oral anticoagulant agents. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。